Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Long-Term Eltrombopag for Bone Marrow Failure Depletes Total Body Iron

David J Young, MDPhD, Xing Fan, MD, Emma Groarke, MD, Bhavisha A Patel, MD, Ronan Desmond, MD, Thomas Winkler, MD, Andre Larochelle, MD PhD, Katherine R. Calvo, MD PhD, Neal S. Young, MD, Cynthia E. Dunbar, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141375

Published: 2020

Journal Articles

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Xing Fan, MD, Thomas Winkler, MD, Ronan Desmond, MD, Bogdan Dumitriu, MD, Danielle M. Townsley, MD MSc, Maria del Pilar Fernandez Ibanez, Fernanda Gutierrez-Rodrigues, PhD, Sophia Grasmeder, RN, Ma Evette Barranta, Diane Madey, Jennifer Lotter, Janet Valdez, Katherine R. Calvo, MD PhD, Colin Wu, PhD, Neal S. Young, MD, Cynthia E. Dunbar, MD

Blood (2018) 132 (Supplement 1): 538.

https://doi.org/10.1182/blood-2018-99-112994

Published: 2018

Journal Articles

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Laura McDonald, MB MRCPI, Peter McCarthy, MB BCh BAO, Mohammad Khan, MD, Patrick Hogan, MB BCh BAO, Eileen C. Kelleher, MD, Philip Murphy, MD, John Quinn, MD PhD, Ronan Desmond, MD, Johnny McHugh, MB, FRPATH, Melanie Strickland, BNS, Mary Cahill, MD, Su Wai Maung, MRCP, MBBS, Clodagh Keohane, MD, Desmond O'Neill, MD, Daniel Ryan, MD, Vitaliy Mykytiv, MD, Helen Enright, MD

Blood (2018) 132 (Supplement 1): 5515.

https://doi.org/10.1182/blood-2018-99-113290

Published: 2018

Journal Articles

Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Thomas Winkler, MD, James N. Cooper, MD, Danielle M. Townsley, MDMSc, Phillip Scheinberg, MD, Sophia Grasmeder, RN, Colin Wu, PhD, Jennifer Lotter, Marie J Desierto, MS, Ronan Desmond, MD, Matthew J. Olnes, MD PhD, Katherine R Calvo, MD PhD, Neal S. Young, MD, Cynthia E Dunbar, MD

Blood (2017) 130 (Supplement 1): 777.

https://doi.org/10.1182/blood.V130.Suppl_1.777.777

Published: 2017

Journal Articles

The Role of Marrow Fibrosis in the Prognosis and Treatment of Myelodysplastic Syndromes: a Single Center Retrospective Study

Emma M Groarke, MRCPI, Su Wai Maung, MRCP, MBBS, FRCPath, Karl Ewins, MRCPI, Michael Jeffers, FRCPath, Johnny McHugh, FRCPath, Ronan Desmond, MD FRCPath, Helen Enright, MD FRCPI, FRCPath

Blood (2016) 128 (22): 5524.

https://doi.org/10.1182/blood.V128.22.5524.5524

Published: 2016

Journal Articles

Successful Treatment of a Diamond-Blackfan Anemia (DBA) Patient with Eltrombopag

Thomas Winkler, MD, Danielle Townsley, MD, Ronan Desmond, MD FRCPath, Bogdan Dumitriu, MD, Sophia Grasmeder, RN, BSN, OCN, Neal S. Young, Cynthia E. Dunbar, MD

Blood (2016) 128 (22): 2682.

https://doi.org/10.1182/blood.V128.22.2682.2682

Published: 2016

Journal Articles

Persistent Elevation of Plasma Thrombopoietin Levels in Severe Aplastic Anemia, Even with Hematologic Recovery

Xin Zhao, MD PhD, Xingmin Feng, PhD, Danielle M. Townsley, MD, Thomas Winkler, MD, Ronan Desmond, MD, Matthew J. Olnes, MD PhD, Harshraj Leuva, Bogdan Dumitriu, MD, Cynthia E. Dunbar, MD, Neal S. Young, MD

Blood (2015) 126 (23): 3609.

https://doi.org/10.1182/blood.V126.23.3609.3609

Published: 2015

Journal Articles

Increased p53 Expression in Patients with Therapy-Related MDS/AML Is Common and May be Associated with a Poor Prognosis

Su Wai Maung, MBBS, MRCP(UK), Niamh Strahan, MSc, Sarah O'Dowd, M.Sc, John O'Loughlin, Ronan Desmond, MD FRCPath, Johnny McHugh, FRCPath, Michael Jeffers, FRCPath, Helen Enright, MD FRCPI, FRCPath

Blood (2015) 126 (23): 5245.

https://doi.org/10.1182/blood.V126.23.5245.5245

Published: 2015

Journal Articles

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Accelerates Count Recovery and Increases Response Rates

Danielle M. Townsley, MD, Bogdan Dumitriu, MD, Phillip Scheinberg, MD, Ronan Desmond, MD, FRCPath, Xingmin Feng, PhD, Olga Rios, RN, Barbara Weinstein, RN, Janet Valdez, PA-C, Thomas Winkler, MD, Marie Desierto, BS, Harshraj Leuva, MBBS, Colin Wu, PhD, Katherine R. Calvo, MD, PhD, Andre Larochelle, MD, PhD, Cynthia E. Dunbar, MD, Neal S. Young, MD

Blood (2015) 126 (23): LBA-2.

https://doi.org/10.1182/blood.V126.23.LBA-2.LBA-2

Published: 2015

Journal Articles

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Su Wai Maung, MBBS, MRCP(UK), Cian McEllistrim, MRCPI, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Margaret Murray, FRCPath, Michael O'Dwyer, MD, Patrick Thornton, FRCPath, Emma Groarke, MRCPI, Denis O'Keeffe, MD MRCPath, Maeve Leahy, MD MRCPath, Aine Burke, MRCP,MD, Peter O'Gorman, Carmel Weldon, M.Sc, MRCPI, Gerard Crotty, MD FRCPath, Meegahage Ratnakanthi Perera, MDMRCPath,MBBS, Cathie Burke, RN, Johnny McHugh, FRCPath, Helen Enright, MD FRCPI, FRCPath, Ronan Desmond, MD FRCPath

Blood (2015) 126 (23): 5258.

https://doi.org/10.1182/blood.V126.23.5258.5258

Published: 2015

Journal Articles

Changes in p53 Expression By Immunohistochemistry during Azacitidine Therapy in Patients with MDS Can Predict Overall Prognosis

Su Wai Maung, MBBS, MRCP(UK), Niamh Strahan, M.Sc, Philomena O'Byrne, M.Sc, Sarah O'Dowd, M.Sc, John O'Loughlin, Ronan Desmond, MD FRCPath, Johnny McHugh, FRCPath, Michael Jeffers, FRCPath, Helen Enright, MD FRCPI, FRCPath

Blood (2015) 126 (23): 2878.

https://doi.org/10.1182/blood.V126.23.2878.2878

Published: 2015

Journal Articles

Alemtuzumab Is Safe and Associated With High Response Rates In Selected Patients With Myelodysplastic Syndrome

Vishal N. Ranpura, MD, Colin O. Wu, Matthew J. Olnes, MD, PhD, Ankur R. Parikh, DO, Aarthi Shenoy, MD, Barbara Weinstein, RN, Phillip Scheinberg, MD, A. John Barrett, Neal S. Young, MD, Christopher S. Hourigan, MD, PhD, Ronan Desmond, MD

Blood (2013) 122 (21): 593.

https://doi.org/10.1182/blood.V122.21.593.593

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Long-Term Eltrombopag for Bone Marrow Failure Depletes Total Body Iron

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

The Role of Marrow Fibrosis in the Prognosis and Treatment of Myelodysplastic Syndromes: a Single Center Retrospective Study

Successful Treatment of a Diamond-Blackfan Anemia (DBA) Patient with Eltrombopag

Persistent Elevation of Plasma Thrombopoietin Levels in Severe Aplastic Anemia, Even with Hematologic Recovery

Increased p53 Expression in Patients with Therapy-Related MDS/AML Is Common and May be Associated with a Poor Prognosis

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Accelerates Count Recovery and Increases Response Rates

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Changes in p53 Expression By Immunohistochemistry during Azacitidine Therapy in Patients with MDS Can Predict Overall Prognosis

Alemtuzumab Is Safe and Associated With High Response Rates In Selected Patients With Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only